Showing results (1441-1450 of 8,886) with videos related to

Sort By:
Pageof 889
European Urology|March 30, 2013
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working GroupCaroline M Moore, Veeru Kasivisvanathan, Scott Eggener, et al.
European Urology|April 2, 2013
European guidelines on upper tract urothelial carcinomas: 2013 updateMorgan Rouprêt, Marko Babjuk, Eva Compérat, et al.
European Urology|April 2, 2013
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstructionMatthias Oelke, Alexander Bachmann, Aurélien Descazeaud, et al.
European Urology|December 5, 2012
Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomyMichael Rink, Emily C Zabor, Helena Furberg, et al.
European Urology|December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
European Urology|December 11, 2012
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trialAndrew Stein, Joaquim Bellmunt, Bernard Escudier, et al.
European Urology|December 11, 2012
The relationship between nutrition and prostate cancer: is more always better?Elizabeth M Masko, Emma H Allott, Stephen J Freedland
European Urology|June 15, 2012
Precise segmental renal artery clamping under the guidance of dual-source computed tomography angiography during laparoscopic partial nephrectomyPengfei Shao, Lijun Tang, Pu Li, et al.
European Urology|May 29, 2012
Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 studyRenzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al.
European Urology|December 1, 2012
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladderChristopher R Chapple, Steven A Kaplan, David Mitcheson, et al.
Pageof 889